Literature DB >> 32862147

Impact of P-Glycoprotein-Mediated Active Efflux on Drug Distribution into Lumbar Cerebrospinal Fluid in Nonhuman Primates.

Yoko Nagaya1, Kazuhide Katayama2, Hiroyuki Kusuhara2, Yoshitane Nozaki2.   

Abstract

Estimation of unbound drug concentration in the brain (Cu,brain) is an essential part of central nervous system (CNS) drug development. As a surrogate for Cu,brain in humans and nonhuman primates, drug concentration in cerebrospinal fluid (CCSF) collected by lumbar puncture is often used; however, the predictability of Cu,brain by lumbar CCSF is unclear, particularly for substrates of the active efflux transporter P-glycoprotein (P-gp). Here, we measured lumbar CCSF in cynomolgus monkey after single intravenous administration of 10 test compounds with varying P-gp transport activities. The in vivo lumbar cerebrospinal fluid (CSF)-to-plasma unbound drug concentration ratios (Kp,uu,lumbar CSF) of nonsubstrates or weak substrates of P-gp were in the range 0.885-1.34, whereas those of good substrates of P-gp were in the range 0.195-0.458 and were strongly negatively correlated with in vitro P-gp transport activity. Moreover, concomitant treatment with a P-gp inhibitor, zosuquidar, increased the Kp,uu,lumbar CSF values of the good P-gp substrates, indicating that P-gp-mediated active efflux contributed to the low Kp,uu,lumbar CSF values of these compounds. Compared with the drug concentrations in the cisternal CSF and interstitial fluid (ISF) that we previously determined in cynomolgus monkeys, the lumbar CCSF were more than triple for two and all of the good P-gp substrates examined, respectively. Although lumbar CCSF may overestimate cisternal CSF and ISF concentrations of good P-gp substrates, lumbar CCSF allowed discrimination of good P-gp substrates from the weak and nonsubstrates and can be used to estimate the impact of P-gp-mediated active efflux on drug CNS penetration. SIGNIFICANCE STATEMENT: This is the first study to systematically evaluate the penetration of various P-glycoprotein (P-gp) substrates into lumbar cerebrospinal fluid (CSF) in nonhuman primates. Lumbar CSF may contain >3-fold higher concentrations of good P-gp substrates than interstitial fluid (ISF) and cisternal CSF but was able to discriminate the good substrates from the weak or nonsubstrates. Because lumbar CSF is more accessible than ISF and cisternal CSF in nonhuman primates, these findings will help increase our understanding of drug central nervous system penetration at the nonclinical stage.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Year:  2020        PMID: 32862147     DOI: 10.1124/dmd.120.000099

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

Review 1.  Choroid Plexus and Drug Removal Mechanisms.

Authors:  Austin Sun; Joanne Wang
Journal:  AAPS J       Date:  2021-05-03       Impact factor: 4.009

2.  Regional Differences in the Absolute Abundance of Transporters, Receptors and Tight Junction Molecules at the Blood-Arachnoid Barrier and Blood-Spinal Cord Barrier among Cervical, Thoracic and Lumbar Spines in Dogs.

Authors:  Hina Takeuchi; Masayoshi Suzuki; Ryohei Goto; Kenta Tezuka; Holger Fuchs; Naoki Ishiguro; Tetsuya Terasaki; Clemens Braun; Yasuo Uchida
Journal:  Pharm Res       Date:  2022-04-29       Impact factor: 4.200

Review 3.  Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier.

Authors:  Raluca Ioana Teleanu; Manuela Daniela Preda; Adelina-Gabriela Niculescu; Oana Vladâcenco; Crina Ioana Radu; Alexandru Mihai Grumezescu; Daniel Mihai Teleanu
Journal:  Pharmaceutics       Date:  2022-05-04       Impact factor: 6.525

4.  Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.

Authors:  Sho Sato; Kota Matsumiya; Kimio Tohyama; Yohei Kosugi
Journal:  AAPS J       Date:  2021-06-03       Impact factor: 4.009

5.  Application of a high-resolution in vitro human MDR1-MDCK assay and in vivo studies in preclinical species to improve prediction of CNS drug penetration.

Authors:  Licong Jiang; Sanjeev Kumar; Marc Nuechterlein; Marissa Reyes; Dao Tran; Clifford Cabebe; Peggy Chiang; James Reynolds; Scott Carrier; Yongkai Sun; Peter Eddershaw; Tanya Hay; Weichao Chen; Bo Feng
Journal:  Pharmacol Res Perspect       Date:  2022-02

6.  Oral etoposide and zosuquidar bioavailability in rats: Effect of co-administration and in vitro-in vivo correlation of P-glycoprotein inhibition.

Authors:  Rasmus Blaaholm Nielsen; René Holm; Ils Pijpers; Jan Snoeys; Ulla Gro Nielsen; Carsten Uhd Nielsen
Journal:  Int J Pharm X       Date:  2021-07-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.